PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Practice Signal

Sepsis Management: Antibiotics, Pressors, and Inotropes

This review helps pharmacists separate the better-supported antibiotic timing and de-escalation practices from the low-certainty, hypothesis-generating vasopressor and inotrope data now emerging in septic shock.

Bottom Line

Across these sources, the strongest practice signal is still early, appropriately selected antibiotics followed by structured reassessment (stewardship time-outs, time-limited inotrope trials), while early multi-vasopressor strategies remain investigational and should not displace the stepwise Surviving Sepsis Campaign (SSC) vasopressor sequence.

−2.10
pct-point mortality difference, timely antibiotics
10 vs 15 days
antibiotic duration, de-escalation
15.6% vs 68.6%
tachyarrhythmias, triple vasopressors
36%
dobutamine early responders

State of Play

Sepsis management rests on early empiric antibiotics, source control, and norepinephrine-first hemodynamic support, but almost every recommendation in this space carries low-certainty evidence. The four sources here are observational cohorts or a small trial, so they refine workflow and monitoring rather than redefine standard therapy.

🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this Practice Signal, every other Signal, and every deep analysis we publish, plus PDF reports.

Subscribe for $8/month →
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.
sepsis septic shock community-onset sepsis abdominal sepsis antibiotic timing antimicrobial stewardship de-escalation ceftriaxone cefepime piperacillin-tazobactam ertapenem norepinephrine
🎓
Synthesized and reviewed by a licensed pharmacist
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.
Thanks for the feedback!

← Back to Evidence Rounds